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Abstract
The objective of this study was to identify, on a symptomatic
knee osteoarthritis (OA) cohort, the risk factors associated with
the progression of the disease. More specifically, we
investigated the correlation between knee cartilage volume loss
from subregions over the span of 24 months by means of
quantitative magnetic resonance imaging (qMRI) with
demographic, clinical, radiological, and MRI structural changes.
A cohort of 107 patients with knee OA selected from a large trial
evaluating the effect of a bisphosphonate underwent x-rays and
MRI of the knee at baseline and 24 months. Joint space width
(JSW) and joint space narrowing (JSN) and cartilage volume
loss over time in subregions of the tibial plateaus and femoral
condyles were quantitated. Structural changes in the
subchondral bone (hypersignal) and in the menisci (tear and
extrusion) were also evaluated.
The greatest cartilage volume loss was found in the medial
compartment, and risk factors included female gender, JSW,
meniscal lesions, and bone changes at baseline. Subregion
analysis revealed that the greatest cartilage volume loss at 24
months was found in the central area of the medial tibial plateau
(15%; p < 0.0001) and of the medial femoral condyle (12%; p
< 0.0001). These findings were associated with the presence at
baseline of meniscal extrusion, particularly severe meniscal
extrusion, medial and severe meniscal tear, bone hypersignal,
high body mass index (BMI), smaller JSW, increases in Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) pain and patient global scores over time, and greater
JSN. Parameters predicting medial central femoral condyle
cartilage volume loss at 24 months were lateral meniscal tear,
SF-36 and BMI at baseline, and JSN. At the medial central tibial
plateau, the parameters were severe meniscal extrusion, severe
lateral meniscal tear, and bone hypersignal in the lateral
compartment at baseline, and WOMAC pain change.
Meniscal damage and bone changes are the features most
closely associated with the greatest subregional cartilage
volume loss. Interestingly, for the first time, JSN was strongly
associated with cartilage loss in the central areas of plateaus
and condyles. This study also further confirms the correlation
between cartilage volume loss and JSN and symptomatic
changes at 24 months.
Introduction
The structural changes in knee osteoarthritis (OA) are charac-
terized mainly by the progressive erosion and loss of articular
cartilage [1]. These changes are often associated with addi-
tional structural changes such as subchondral bone lesions,
which include remodelling and cysts, and alterations in the
BMI = body mass index; DMOAD = disease-modifying osteoarthritis drug; FISP = fast inflow with steady-state precession; JSN = joint space nar-
rowing; JSW = joint space width; MRI = magnetic resonance imaging; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; qMRI = 
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menisci, which include degeneration, tear, and extrusion [2,3].
Conventional x-rays have been used and continue to be used
to assess some of these changes, particularly in the evaluation
of disease progression. However, the use of x-rays to assess
and quantify structural changes over time does present some
serious limitations, including the fact that this technology does
not permit direct visualization of cartilage) [4-7].
In the last decade, remarkable progress in the development of
imaging technology has been made. Magnetic resonance
imaging (MRI) now allows not only the direct visualization of
joint structure but also the quantitative assessment of changes
over time. A number of semiquantitative scoring systems and
quantitative technologies have been developed to achieve this
goal [8]. Most of the work has concentrated on the measure-
ment of cartilage volume/thickness and the assessment of
changes to evaluate the evolution of OA lesions in cross-sec-
tional and longitudinal studies. Some of these studies have
been highly instrumental in providing a significant amount of
new information. For instance, they have shown that disease
progression is not consistent among patients suffering from
knee OA and that a number of factors are associated with a
risk of more aggressive progression. These risk factors include
higher body mass index (BMI), meniscal tear/extrusion, and
subchondral bone marrow hypersignal or edema [2,5,7,9-11].
To date, correlations between the global or regional loss of
cartilage and disease symptoms or patient function have sel-
dom been studied and correlations between x-ray and MRI
data with respect to cartilage loss are recognized in general as
not very strong) [4-7]. Studies using quantitative MRI (qMRI)
have demonstrated that the loss of cartilage volume in patients
with knee OA is generally progressive over time and is usually
greater in the medial compartment than the lateral compart-
ment [2,4,7,11,12]. However, in these patients, very little infor-
mation is available on the evolution of cartilage loss over time
in the more focal regions, such as the subregions of the knee
compartments, and on whether patients with rapid versus slow
disease progression have the same evolution. Even less infor-
mation is available on the relationship between these lesions
and associated risk factors, disease signs and symptoms, and
x-ray changes. Therefore, the main aim of this study was to
identify the structural changes in OA, which could explain the
progression of symptoms, and thereby provide a better under-
standing of the natural evolution of the disease. This informa-
tion is essential to the design of clinical trials and the
development of new therapeutic disease-modifying OA drug
(DMOAD) strategies.
Materials and methods
Patient selection
A subset of 110 patients (107 completed the study) was
selected from 1,232 patients from North America enrolled in a
large clinical trial evaluating the impact of risedronate, a
bisphosphonate, on knee OA as previously described [13]. In
this latter study, the patients were randomly assigned equally
into four treatment groups: placebo, risedronate 5 mg/day,
risedronate 15 mg/day, or risedronate 50 mg/week. The
patients [13] had symptomatic disease that required medical
treatment in the form of acetaminophen, traditional nonsteroi-
dal anti-inflammatory drugs (NSAIDs), or selective cyclooxyge-
nase-2 inhibitors. Eligible patients were required to display
radiological evidence of OA of the affected knee on a radio-
graph obtained within 6 months of the outset of the study.
Finally, patients had to have a minimum joint space width
(JSW) of the medial compartment of between 2 and 4 mm, at
least one osteophyte, and a narrower medial compartment
compared with the lateral compartment. The measurements
were done from a baseline film using the standardized semi-
flexed view, which was contrasted with follow-up films [7,13].
No patient had sole lateral compartment disease.
Patients were excluded if they had chondrocalcinosis or an
acute or chronic infection (including tuberculosis) or if their
OA of the knee was secondary to other conditions. Further
exclusion factors included history of past or present gastroin-
testinal ulceration, receipt of an intra-articular corticoid injec-
tion in the study knee within the 6 months prior to the outset
of the study, as well as classification as radiological grade IV
on the Kellgren-Lawrence scale for the study knee or severe
(class IV) functional disability. In the case of patients with two
symptomatic knees, the more symptomatic knee was chosen
for the investigation. Patients were permitted to receive simple
analgesics or NSAIDs, with the exception of indomethacin
[14], the regimens of which could be changed according to
the preference of the rheumatologist and the clinical course of
the patient. Such regimens, as well as any changes to them,
were closely monitored and noted. A centralized ethics com-
mittee approved this study, and each patient gave informed
consent.
Clinical evaluation
Patients underwent clinical evaluation at baseline and every 6
months thereafter until 24 months. They were first evaluated
on the basis of the Western Ontario and McMaster Universi-
ties Osteoarthritis Index (WOMAC) [15], using its French-
Canadian translation [16]. In addition, the patients themselves
used a visual analog scale to make a global assessment of
their condition (patient global assessment: 0 = very good; 100
= very bad) and to rate the pain they were experiencing that
day (patient pain score: 0 = no pain; 100 = most severe pain).
Finally, the SF-36, a generic quality-of-life instrument, was
administered to the patients at each visit [17]. A washout of
medications was done prior to the clinical evaluation; NSAIDs
were discontinued at least 48 hours prior to the investigation
and acetaminophen, 24 hours. The clinical evaluators were
blinded to the results of previous radiological or MRI data.
Knee x-rays
The JSW of the target knees at baseline and 24 months of fol-
low-up, at the narrowest point in the medial tibio-femoralAvailable online http://arthritis-research.com/content/9/4/R74
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compartment, was measured according to the published pro-
tocol by means of an automated computerized method of
measurement [18,19]. In the rare occurrence that the radio-
graphic quality of the film prevented the implementation of
automatic JSW measurement software, manual intervention
was required [20]. The variation coefficient for JSW measure-
ment for the original reliability study was 1% for repeat radio-
graphs (test/retest) of the knee in the semiflexed position [18].
The reproducibility of the method was also reassessed [21];
data showed that 45% of the examinations achieved high qual-
ity (that is, JSW difference between repeat films of less than
0.1 mm) and 92% achieved excellent to good quality with a dif-
ference between repeat films of 0.3 mm.
Knee magnetic resonance imaging
High-resolution, three-dimensional MRI for each patient with
OA (baseline and 24 months) was acquired using the com-
mercially available Magnetom Vision 1.5 Tesla machine with
integrated knee coil (Siemens, Erlangen, Germany) as previ-
ously described [22,23]. These exams are optimized three-
dimensional fast inflow with steady-state precession (FISP)
acquisitions with fat suppression. This registration procedure
previously demonstrated excellent intra- and inter-reader cor-
relations [23].
The cartilage volume (cubic millimeters) was calculated
[22,23] and change in cartilage volume over time was calcu-
lated compared with baseline in absolute values (cubic millim-
eters) and expressed as a percentage as previously described
[22]. The cartilage volume was evaluated in different regions
by means of the WORMS (whole-organ magnetic resonance
imaging score) system [24] with slight modification (Figure 1).
The femoral articular and trochlear surfaces were divided into
medial and lateral regions. The medial and lateral femurs were
each divided into three regions: anterior, central, and poste-
rior. The medial tibial plateau and lateral tibial plateau were
each divided into three equal regions (anterior, central, and
posterior) or in concentric zones: border and center rings.
Meniscal and bone lesions
The evaluation of meniscal and bone structure was performed
using the same sequences as those used for the cartilage
assessment [2]. The FISP sequence enabled visualization of
the meniscal tissue and bone lesions with enough clarity to
adequately and reliably perform the semiquantitative scoring
system. A semiquantitative assessment of meniscal lesions
and bone hypersignal (edema) was performed by an experi-
enced radiologist (M-JB) who was blinded to the time
sequences and cartilage volumes.
The scoring system [2,7] for meniscal damage referred to the
accepted MRI nomenclature for meniscal anatomy [25,26]. In
brief, the section of the menisci affected by tear or extrusion
was scored separately using the semiquantitative scales [2].
Meniscal tear assessment was as follows: 0 = no damage, 1
= 1 out of 3 meniscal areas involved (anterior, middle, and pos-
terior horns), 2 = 2 out of 3 involved, and 3 = all 3 areas
involved (severe tear). The extent of meniscal extrusion on the
medial or lateral edges of the femoro-tibial joint space, not
including the osteophytes, was evaluated for the anterior, mid-
dle, and posterior horns of the menisci in which 0 = no extru-
sion, 1 = partial meniscal extrusion, and 2 = complete
meniscal extrusion with no contact with the joint space (severe
extrusion).
For bone hypersignal, the extent of the lesion was assessed in
the medial and lateral tibio-femoral compartments (as previ-
ously described [7]) with the following semiquantitative scale:
0 = absence of hypersignal; 1 = mild to moderate hypersignal
(a small- or medium-sized lesion); and 2 = severe hypersignal
(a large-sized lesion). The results are presented by either
absence or presence of any hypersignal (grade 1 or 2) or by
presence of one severe hypersignal lesion (grade 2 only),
regardless of the presence of additional smaller lesions. The
reliability of both scoring systems for meniscal and bone
changes was previously demonstrated to be excellent [7].
Statistical analysis
All of the data (clinical, radiological, and laboratory) were sys-
tematically entered into a computerized database using a
blinded double-entry procedure, after which descriptive statis-
tics for patient characteristics were tabulated. The cartilage
Figure 1
Graphic representation of the cartilage subregions as described in  Table 2 Graphic representation of the cartilage subregions as described in 
Table 2. Of note is that the greatest cartilage volume loss at 24 months 
was found for the femoral condyle at the medial central and anterior 
regions and for the tibial plateau at the medial center ring and central 
region (shading from center).Arthritis Research & Therapy    Vol 9 No 4    Pelletier et al.
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volume losses are presented as percentage losses compared
with baseline (mean ± standard deviation) and statistical rele-
vance assessed by a one-sample Student t test. A set of anal-
yses was done by dividing the cohort into quartiles of cartilage
volume loss, the first quartile demonstrating greater cartilage
volume loss. Statistical relevance was assessed using a Fisher
exact test for categorical data and a two-sided Student t test
for continuous data. The relationship between subregion car-
tilage volume loss at 24 months and the patient baseline char-
acteristics, such as demographics, symptoms, JSW, and other
MRI findings, was investigated using the Spearman correlation
test. Finally, multivariate forward stepwise correlations were
used to assess predictors of cartilage volume loss independ-
ently of potential confounders. All statistical analyses were
done using Statistica, version 7 (StatSoft, Inc., Tulsa, OK,
USA). All tests were two-sided, and a p value of 0.05 was con-
sidered statistically significant. Analyses were not corrected
for multiple comparisons.
Results
Patient characteristics
A total of 107 out of 110 patients were assessed with qMRI;
three patients were lost to follow-up. At baseline, the cohort
demographics and characteristics were largely in line with the
OA population of the main study [13]: the mean age was 62.4
± 7.5 years, 64% of subjects were female, subjects had an
average BMI of 30.6 ± 4.3 kg/m2, the duration of knee OA was
8.9 ± 7.2 years, 91.4% were taking analgesics and 72% were
taking NSAIDs, and these patients were exhibiting disease
activity scores in the mild to moderate range according to the
WOMAC (total: 38.9 ± 22.9), the patient global (visual analog
scale: 48.2 ± 5.0), the SF-36 (38.1 ± 9.5), and the Kellgren-
Lawrence (grade 2: 53% of the patients; grade 3: 47%)
scales. The mean JSW measurement at baseline was 2.88 ±
0.64 mm.
The patient cohort population characteristics at baseline were
first analyzed by quartile, separating those with the greatest
loss (first quartile) of global and medial cartilage volume from
those with the least loss (fourth quartile). Data from global vol-
ume (Table 1) showed that the greatest risks for rapid progres-
sion from the demographic characteristics were the body
weight (p < 0.07) and the BMI (p < 0.06). From a structural
point of view, the most predominant risk factors were the pres-
ence of a severe medial meniscal tear (p < 0.01) or medial
meniscal extrusion (p < 0.02) and the most statistically signif-
icant risk was associated with the severe medial meniscal
extrusion (complete extrusion; p  < 0.0001). Moreover, the
presence of a bone marrow hypersignal in the lateral compart-
ment was also associated with a greater risk (p < 0.005). For
the medial compartment (Table 1), the greatest risks from the
demographic characteristics were the female gender (p  <
0.05), the BMI (p < 0.07), and the SF-36 (p < 0.07). Of note
was the strongly predictive value of the JSW at baseline (p <
0.01). From the structural changes, the risk factors were simi-
lar to those found for the global volume with the addition of the
medical meniscal tear (p < 0.02) and the bone hypersignal in
the medial compartment (p < 0.06).
Cartilage volume loss on condyles, plateaus, and 
subregions
The analysis of the cartilage volume/thickness loss in the dif-
ferent anatomical areas of the knee was most informative. The
greatest percentage of cartilage volume loss over time (24
months) was found in the medial condyle and plateau, fol-
lowed in order by the lateral plateau and the trochlear area
(Figure 1; Table 2). Further analysis by subregion indicated
that the greatest loss of cartilage volume on the condyles was
occurring in the central (weight-bearing) and anterior portions
of the medial condyle. At the trochlear level, the greatest loss
was on the medial section. On the tibial plateaus, the maximum
loss was found on the medial plateau and was approximately
35% greater than that found on the lateral plateau. Plateau
subregion analysis revealed findings similar to those for the
condyles. The maximum loss was found in the central (weight-
bearing) portion of the medial plateau followed by the anterior
and then the posterior section. On the lateral plateau, the max-
imum loss was also found, as for the medial plateau, on the
central weight-bearing area. However, in contrast to the latter,
a much greater loss was found on the posterior section than
on the anterior section. Compared with baseline, each of the
subregions, except for the anterior and posterior subregions of
the lateral condyle and anterior subregion of the tibial plateau,
was statistically different (p < 0.0001) (Table 2).
Correlations between cartilage volume loss at 24 months 
in the central areas of the medial compartment and the 
demographic, clinical, structural, and joint space width 
data
The analyses focused first on MRI data from the central areas
of the medial compartment as they presented the greatest loss
of cartilage volume and were therefore the areas of the most
significance (Table 3). From the baseline demographic char-
acteristics, a positive and significant correlation was found
with the BMI at the regions of interest, which included the cen-
tral femoral condyle and plateau and the two subregions com-
bined together (compartment). With regard to the structural
changes, correlations were obtained for the cartilage loss in
the central area of the medial femur and tibia and both subre-
gions combined, compared with JSW, the presence of menis-
cal extrusion and severe meniscal extrusion, severe medial
meniscal tear, and the subchondral bone marrow hypersignal,
particularly in the lateral compartment. There was also a corre-
lation between the loss of cartilage in the medial central femo-
ral condyle and the presence of lateral meniscal tear. For JSW
at baseline, a trend was found between alcohol consumption
and statistical significance with medial meniscal tear and
severe medial meniscal tear. With regard to the changes in
clinical variables at 24 months and the loss of cartilage, data
revealed significant correlations between the clinical criteriaAvailable online http://arthritis-research.com/content/9/4/R74
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WOMAC pain score change at the plateau and medial com-
partment levels. There was also a trend between the patient
global change and the medial compartment. For the x-rays, a
significant correlation was obtained between the joint space
narrowing (JSN) and the WOMAC total as well as with the
WOMAC pain and function subscales. The loss in JSW (JSN)
was significantly correlated with the loss of cartilage volume
on the central weight-bearing area of the condyles and the pla-
teaus as well as on the medial compartment.
Forward stepwise multivariate correlations
The most statistically significant independent predictors of the
loss of cartilage volume in the central area of the medial femo-
ral condyles (Table 4) at baseline were (in order of signifi-
cance) the loss of joint space (JSN), the presence of a lateral
meniscal tear, the SF-36 score, the BMI, and to a lesser extent
the JSW. Interestingly, the most significant independent pre-
dictors of the loss of cartilage volume in the central area of the
medial tibial plateaus (Table 5) were to some extent different
from those found for the femoral condyle. These include (in
order of significance) the presence of a severe meniscal extru-
sion, an increase in the WOMAC pain score, the presence of
bone hypersignal and severe meniscal tear in the lateral com-
partment, and to a lesser extent the WOMAC stiffness.
The risk factors associated with the loss of cartilage volume in
the central subregions of the medial compartment (combina-
tion of femoral condyle and tibial plateau) (Table 6) were (in
order of significance) the presence of a severe meniscal extru-
sion, the JSN, the presence of a bone hypersignal in the lateral
compartment, and alcohol consumption.
Discussion
This longitudinal study provides new and interesting informa-
tion about the risk factors associated with the rapid advance-
ment of the disease progression (cartilage loss) in patients
with symptomatic OA. It also brings to light new and unique
information about the topographical loss of cartilage in the
different subregions of the knee and the associated risk
factors. Moreover, the impact of the location and rate of
cartilage loss on the evolution of OA symptoms over time was
thoroughly explored. Treatment with risedronate did not inter-
fere with the actual results of the study as the drug was shown
to have no significant effect on the loss of cartilage volume [7],
on other structural changes, or on the disease symptoms or
JSW changes over time [7,13].
The global (continuous) analysis of these data was previously
done and provides very informative findings [7]. However, to
Table 1
Patient characteristics at baseline: first versus fourth quartile based on cartilage volume loss
Global Medial compartment
First quartile
(greatest loss)
(n = 27)
Fourth quartile
(least loss)
(n = 27)
P value First quartile
(greatest loss)
(n = 27)
Fourth quartile
(least loss)
(n = 27)
P value
Age 63.7 ± 7.2 61.3 ± 7.5 0.23 64.1 ± 7.4 61.6 ± 7.8 0.24
Female 58% 67% 0.50 48% 74% 0.05
Weight (kg) 84.9 ± 14.9 77.6 ± 14.3 0.07 86.3 ± 14.9 78.6 ± 16.3 0.07
Body mass index 31.4 ± 3.9 29.1 ± 4.9 0.06 31.4 ± 3.6 29.6 ± 4.8 0.14
Joint space width (mm) 2.84 ± 0.54 3.06 ± 0.64 0.18 2.70 ± 0.67 3.18 ± 0.66 0.01
WOMAC pain 38.8 ± 22.1 35.4 ± 23.7 0.54 37.3 ± 23.2 34.1 ± 23.0 0.60
WOMAC function 44.3 ± 23.3 38.0 ± 24.8 0.34 43.6 ± 23.9 37.2 ± 24.8 0.33
SF-36 39.0 ± 8.8 34.8 ± 9.8 0.10 40.2 ± 8.3 35.9 ± 8.4 0.07
Severe medial meniscal tear 50% 19% 0.01 51% 11% 0.002
Medial meniscal tear 85% 81% 0.76 92% 66% 0.02
Severe medial meniscal extrusion 54% 7% 0.0001 56% 7% 0.0003
Medial meniscal extrusion 81% 52% 0.02 82% 48% 0.01
Bone hypersignal 77% 48% 0.03 81% 37% 0.002
Bone hypersignal in the medial compartment 62% 48% 0.34 59% 33% 0.06
Bone hypersignal in the lateral compartment 50% 15% 0.005 59% 15% 0.001
Values are mean ± standard deviation, p values are two-sided Student t test; or values are in percentage, p values are Fisher exact test. WOMAC, 
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further explore the risk factors that are selectively associated
with more rapid disease progression, we performed analysis of
cartilage volume loss by quartile in which we segregated the
first quartile (greatest loss) from the fourth (least loss).
Patients from the first quartile are of particular interest from a
clinical perspective as they are likely to have the worst progno-
sis and are therefore at greater risk of surgical intervention for
joint replacement. Moreover, they are of special interest for
Table 2
Cartilage volume in absolute value (mm3) and change over 24 months follow-up from baseline
Baseline (mm3) 24 months (mm3) Change at 24 months (mm3) Change at 24 months (percentage)
Femoral condyle
Medial 2,228.9 ± 609.1 2,028.3 ± 585.1 -201.5 ± 178.6 -9.1 ± 7.5
Lateral 2,155.2 ± 677.6 2,105.8 ± 654.3 -43.8 ± 94.5 -2.0 ± 4.6
Trochlea 2,974.4 ± 901.4 2,835.7 ± 849.5 -123.8 ± 156.6 -4.1 ± 5.1
Transversal subregions
Medial
Posterior 840.6 ± 240.5 802.7 ± 236.5 -37.9 ± 70.2 -4.4 ± 7.9
Central 729.2 ± 240.3 643.3 ± 232.9 -87.9 ± 90.4 -12.0 ± 11.5
Anterior 659.2 ± 213.3 582.2 ± 212.0 -75.7 ± 72.8 -12.4 ± 12.0
Trochlea 1,307.6 ± 404.9 1,225.7 ± 365.0 -77.8 ± 90.9 -5.5 ± 6.1
Lateral
Posterior 578.6 ± 192.9 571.9 ± 193.1 -4.8 ± 43.5 -0.9 ± 7.6
Central 931.9 ± 323.8 903.0 ± 312.2 -28.3 ± 53.4 -2.9 ± 6.2
Anterior 644.7 ± 210.2 631.0 ± 203.2 -10.8 ± 32.5 -1.7 ± 5.6
Trochlea 1,666.7 ± 537.8 1,610.1 ± 529.9 -46.0 ± 98.7 -3.0 ± 6.8
Tibial plateau
Medial 1,320.4 ± 419.9 1,195.0 ± 373.2 -126.0 ± 117.0 -9.3 ± 7.5
Lateral 1,673.8 ± 520.8 1,563.1 ± 466.9 -101.9 ± 98.1 -6.1 ± 5.7
Concentric zones
Medial
Border ring 709.0 ± 242.0 660.1 ± 211.9 -47.9 ± 57.1 -6.2 ± 6.3
Center ring 611.4 ± 192.6 534.9 ± 181.8 -78.1 ± 70.0 -13.0 ± 10.9
Lateral
Border ring 790.2 ± 249.1 746.3 ± 224.0 -39.0 ± 44.3 -5.0 ± 5.7
Center ring 883.6 ± 286.1 816.8 ± 260.3 -62.9 ± 60.3 -7.2 ± 7.8
Transversal subregions
Medial
Posterior 397.6 ± 140.5 380.1 ± 128.4 -17.1 ± 36.1 -3.7 ± 7.7
Central 566.7 ± 191.6 484.6 ± 179.7 -84.2 ± 72.4 -15.0 ± 12.0
Anterior 356.1 ± 130.2 330.3 ± 116.7 -24.7 ± 36.0 -6.8 ± 10.3
Lateral
Posterior 515.5 ± 176.7 474.9 ± 154.5 -36.6 ± 41.3 -7.1 ± 8.9
Central 791.7 ± 265.4 729.7 ± 244.4 -59.5 ± 56.0 -7.8 ± 8.4
Anterior 366.5 ± 122.3 358.4 ± 115.2 -5.8 ± 18.3 -1.6 ± 5.0
The data are the mean ± standard deviation. The p values from one sample two-sided Student t test in the change of cartilage volume are less than 
0.0001 for all regions except for the lateral femoral condyle at the anterior and posterior areas and for the lateral tibial plateau at the anterior area.Available online http://arthritis-research.com/content/9/4/R74
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Table 3
Univariate Spearman correlations with cartilage loss at 24 months
Baseline 
characteristics
Medial central femoral condyle Medial central tibial plateau Both areas (medial compartment) Joint space width (mm)
P value P value P value P value
Age -0.13 0.18 -0.07 0.49 -0.11 0.26 -0.05 0.58
Gender 0.12 0.24 0.08 0.41 0.11 0.26 0.04 0.66
Body mass index -0.21 0.03 -0.21 0.03 -0.23 0.02 -0.07 0.48
Alcohol 0.02 0.86 0.02 0.82 0.02 0.82 0.18 0.06
Smoking 0.74 0.45 0.09 0.36 0.09 0.35 0.06 0.55
SF-36 -0.14 0.14 -0.03 0.79 -0.09 0.34 -0.05 0.61
WOMAC total -0.05 0.61 -0.02 0.82 0.02 0.88 0.08 0.41
WOMAC subscale
Pain 0.10 0.30 0.05 0.58 0.09 0.38 0.14 0.14
Stiffness 0.04 0.68 -0.07 0.46 -0.06 0.52 -0.0005 0.99
Function -0.05 0.62 -0.03 0.76 0.01 0.92 0.08 0.42
Patient global 0.04 0.65 0.12 0.90 0.03 0.75 -0.0004 0.99
Joint space width 
(mm)
0.29 0.003 -0.28 0.03 0.32 0.001 -- --
Meniscal extrusion -0.31 0.001 -0.26 0.007 -0.32 0.001 -0.16 0.11
Severe meniscal 
extrusion
-0.33 0.001 -0.40 0.0001 -0.41 0.0001 -0.16 0.10
Medial meniscal 
tear
-0.26 0.006 -0.11 0.25 -0.21 0.03 -0.32 0.001
Severe medial 
meniscal tear
-0.36 0.0001 -0.29 0.003 -0.36 0.0001 -0.32 0.001
Lateral meniscal 
tear
0.21 0.03 0.05 0.60 0.15 0.13 -0.09 0.33
Severe lateral 
meniscal tear
0.07 0.49 0.04 0.65 0.06 0.52 0.16 0.11
Bone hypersignal -0.26 0.008 -0.23 0.02 -0.27 0.005 -0.11 0.25
Bone hypersignal in 
the medial 
compartment
-0.11 0.23 -0.10 0.30 -0.12 0.21 -0.03 0.76
Bone hypersignal in 
the lateral 
compartment
-0.32 0.001 -0.31 0.001 -0.35 0.0001 -0.13 0.17
Changes in 
selected clinical 
variables at 24 
months
Medial central femoral condyle Medial central tibial plateau Both areas (medial compartment) Joint space narrowing
P value P value P value P value
SF-36 0.07 0.44 0.12 0.23 0.11 0.27 0.10 0.31
WOMAC total -0.05 0.58 -0.10 0.31 -0.09 0.38 -0.23 0.02
WOMAC subscale
Pain -0.15 0.12 -0.21 0.03 -0.21 0.03 -0.29 0.002
Stiffness 0.02 0.85 -0.03 0.74 0.009 0.93 -0.18 0.07
Function -0.04 0.68 -0.07 0.45 -0.06 0.51 -0.23 0.02
Patient global -0.17 0.08 -0.17 0.08 -0.19 0.05 -0.02 0.83
Joint space 
narrowing
0.40 0.003 0.21 0.003 0.34 <0.0001 -- --
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.Arthritis Research & Therapy    Vol 9 No 4    Pelletier et al.
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DMOAD studies as they may be the most likely to respond to
treatment [27].
The results of this study with regard to the quartile analysis
show that OA patients experiencing the greatest risk of carti-
lage loss (first quartile), and more particularly in the medial
compartment, were female and had a higher BMI. There was,
however, no difference at baseline in disease symptoms or
patient function. Interestingly, these patients showed a signifi-
cantly narrower JSW. From a structural point of view, severe
medial meniscal tear and/or extrusion or subchondral bone
marrow hypersignal predominantly in the lateral compartment
were clearly the most significant risk factors (Table 1). These
are in line with some of our findings from previous analyses
[2,7] and with the work of other investigators [9,11,28,29].
There are, however, some exceptions. For instance, the asso-
Table 4
Parameters predicting medial central femur cartilage volume loss at 24 months: stepwise forward multivariate regression
Beta coefficient Standard error of beta P value
Joint space narrowing 0.29 0.08 0.0005
Lateral meniscal tear 0.24 0.08 0.005
SF-36 -0.22 0.09 0.02
Body mass index -0.19 0.09 0.03
Joint space width (mm) 0.18 0.10 0.06
Alcohol -0.15 0.08 0.07
Correlations were done with baseline values. Values were adjusted by factors listed in Table 3.
Table 5
Parameters predicting medial central tibia cartilage volume loss at 24 months: stepwise forward multivariate regression
Beta coefficient Standard error of beta P value
Severe meniscal extrusion -0.33 0.09 0.0004
WOMAC pain (change) -0.26 0.09 0.007
Bone hypersignal in the lateral compartment -0.19 0.09 0.03
Severe lateral meniscal tear 0.21 0.09 0.02
WOMAC stiffness -0.16 0.09 0.07
Correlations were done with baseline values unless otherwise indicated. Values were adjusted by factors listed in Table 3. WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis Index.
Table 6
Parameters predicting the medial central subregiona cartilage volume loss at 24 months: stepwise forward multivariate regression
Beta coefficient Standard error of beta P value
Severe meniscal extrusion -0.28 0.10 0.004
Joint space narrowing 0.18 0.09 0.03
Bone hypersignal in the lateral compartment -0.19 0.09 0.04
Alcohol -0.17 0.09 0.04
Severe medial meniscal tear -0.16 0.09 0.08
Severe lateral meniscal tear 0.15 0.09 0.08
Body mass index -0.15 0.09 0.09
aMedial central femur and tibia combined. Correlations were done with baseline values. Values were adjusted by factors listed in Table 3.Available online http://arthritis-research.com/content/9/4/R74
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ciation of the extent of cartilage loss with disease symptoms
and, more precisely, with the WOMAC and SF-36 scores was
lost, although a trend was found for the SF-36. We believe that
this may be due to a type II error given that the groups of
patients in the present analysis were relatively small. However,
other explanations are also possible (for example, the cross-
sectional nature of this type of analysis which also imposes
limitations on our results).
These results are of great interest and have practical implica-
tions as they show that factors that can predict disease pro-
gression can be identified at the time that patients are
included in clinical studies, as previously mentioned. These
findings may also have particular relevance to DMOAD trials,
as the selection of patients who present little or no progres-
sion of structural changes, specifically cartilage loss over time,
represents a major challenge. This is particularly true with
respect to the calculation of the number of patients to be
included in a clinical trial. It also raises the important issue of
the relevance of performing patient stratification at baseline
during clinical trials.
Our findings on the key role played by the meniscus in OA car-
tilage pathology and loss nicely complement a number of pre-
vious reports. For example, MRI studies that have examined
the role of meniscal lesions in OA and non-OA populations
have reported that these changes [28,30] are correlated with
a greater risk of cartilage loss [9]. The findings of this study are
supported by both univariate and multivariate analyses. Similar
findings were reported with meniscal malposition in patients
with symptomatic knee OA [9] and in patients who had under-
gone partial meniscectomy [31]. Taken together, these find-
ings stress the very important role played by the meniscal
structure and positioning in protecting the integrity of cartilage
in both healthy and OA individuals. Our data, however, clearly
point to the fact that by far the greatest risk was associated
with the presence of a complete (severe) extrusion of the
medial meniscus. These findings support the hypothesis that
the meniscus exerts a direct protective effect by reducing the
physical contact between the cartilage surfaces. They also
point to a protective effect of the meniscus even in the
presence of degenerative changes as long as it remains in its
normal positioning.
The present study showed that bone marrow hypersignal was
also a risk factor for rapid loss of cartilage for the global knee
and in the medial compartment. Interestingly, it was the pres-
ence of a bone hypersignal in the lateral compartment that was
found to be the most significant risk factor. The relationship
between bone marrow hypersignal and severity of knee OA
cartilage lesions was first shown by Hunter and colleagues
[29] and Felson and colleagues [32]. The compartmental
edema was correlated with local cartilage loss as well as with
limb alignment (medial lesions being associated with varus
limbs and lateral lesions with valgus limbs). In the present
study, any patients with clinically significant malalignment
were excluded. However, although an examination was per-
formed, there was no precise measurement of joint alignment.
Thus, no firm conclusion can be arrived at as to the role played
by malalignment in the present study. The exact reasons for
the relationship between the presence of bone marrow hyper-
signal in the lateral compartment and the rapid loss of cartilage
in the medial compartment remain unexplained and require fur-
ther exploration. Though speculative, one possible explanation
could be that patients experiencing such damage tend to shift
their weight, putting more biomechanical stress on the lateral
compartment.
The evaluation of cartilage loss by means of subregional anal-
ysis provides most interesting information. The loss was much
greater in the medial compartment for both femoral condyles
and tibial plateaus. This sensitivity to change being greater in
the medial compartment was somewhat expected as patients
selected for this study had baseline OA that was predominant
in this particular compartment. These data support the validity
of such outcome measures. On the femoral condyle, the loss
was found in the central and anterior sections, followed by the
trochlear area. These findings are in line with the work of Amin
and colleagues [4] in patients with knee OA with meniscal
lesions and that of Biswal and colleagues [30] in patients with
meniscal tears who had undergone meniscectomies, with the
exception that the preferential loss of cartilage occurring at the
posterior medial femoral condyle found in these two studies
was not confirmed in our OA population. The loss of cartilage
on the lateral condyle followed the same pattern as the medial
condyle but with the loss being less pronounced. The loss of
cartilage on the tibial plateaus was identified mainly in the cen-
tral area, which is not covered by the menisci. In addition, the
pattern of loss in transversal subregions was found to be dif-
ferent between the two plateaus; in the medial plateau a
greater loss was found in the anterior area, whereas on the lat-
eral plateau it was on the posterior area. These differences
point to the possibility that risk factors leading to cartilage loss
could have been different in each tibial plateau. The low inci-
dence of meniscal lesions in the lateral compartment [2] points
to the likelihood that other factors, such as bone marrow
hypersignal, may play a more predominant role at that level, as
indicated by the results from the quartile analysis. However, on
the medial side, the preferential loss of cartilage in the central
and anterior areas correlates closely with the high prevalence
of tear/extrusion at that level, since no posterior lesions could
be found in these patients [2].
Comparative data from the MRI and x-rays indicate that the
MRI is a more comprehensive tool for globally identifying fac-
tors that are predictive of the progression of the disease. Both
the JSN and the cartilage volume loss were found to be posi-
tively correlated with the worsening of pain. The cartilage loss
also correlates with the patient global score, and JSN with the
loss of function. However, there was not good concordanceArthritis Research & Therapy    Vol 9 No 4    Pelletier et al.
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between the two methods, with the exception of the WOMAC
pain. Again, this may be due to the limitations imposed by the
univariate analysis.
This study also provides clear evidence of a correlation
between the loss of cartilage on weight-bearing areas and OA
disease symptoms. The predictive value of the SF-36 indicates
that the patients at high risk of progression are usually more
disabled by the disease. They also experienced an increase in
the level of knee pain, and, to a lesser extent, joint stiffness
over time as the disease progressed. The relationship
between the worsening in the WOMAC scores with the loss
of cartilage on the central portion of the tibial plateau is intrigu-
ing. The level of significance of these findings for the WOMAC
pain is greater than those previously reported for the loss of
cartilage volume in the entire medial compartment [7]. Moreo-
ver, the trend toward correlation with joint stiffness is a new
and most interesting finding, as there is, to date, very little
information of this kind originating from longitudinal studies.
However, from cross-sectional studies, there have been
reports of the correlation of knee pain with full-thickness carti-
lage defects [3,6] and bone marrow lesions [3,6,32]. Such a
study discriminating subregions is of great significance in
DMOAD trials as the effect of drug treatment on structural
changes needs to be correlated with disease symptoms.
Our findings provide new information about the possible cor-
relation between the loss of cartilage volume assessed by MRI
and the loss of JSW assessed by x-ray. Previous studies con-
ducted by our group [7,22] demonstrated the absence of cor-
relation between the loss of cartilage volume in the entire
medial compartment and the JSW in patients with knee OA.
These findings were in line with the previous report of Amin
and colleagues [4]. However, in the present study, a very
strong correlation was found between the JSN and the loss of
cartilage in the central area of the medial femoral condyle and,
to a lesser extent, with the loss on the medial central tibial pla-
teau. These findings are in close accordance with patient knee
positioning during x-ray exams. Therefore, the standard x-ray
technique and consequently JSW measurement commonly
used in clinical trials accurately assess the focal loss of
cartilage in patients with knee OA in the medial condyle and
plateau subregions. Compared with x-rays, MRI presents sig-
nificant advantages in assessing the change in cartilage
volume/thickness in all the other subregions and
compartments of the knee in addition to providing information
on other structural changes, including the meniscus and
subchondral bone. The latter are most relevant in identifying
predictive factors of disease progression. Moreover, the eval-
uation of changes in both medial and lateral compartments is
imperative given that a recent study demonstrated that some
drugs may have a preferential chondroprotective effect on the
loss of cartilage in the lateral compartment [27].
This study has obvious limitations, the main one being the rel-
atively small number of patients included in the analyses. New
studies are under way or have been recently completed [27]
and should provide additional information and hopefully con-
firm the present findings. Another limitation is the fact that
some patients received treatment with risedronate. All efforts
have been made to ensure that this had no impact on the
actual findings; the published data from the entire patient
cohort analysis are certainly supportive to that effect [13].
Conclusion
This study provides new information on the risk factors associ-
ated with the loss of cartilage and the evolution of symptoms
in patients with knee OA in which meniscal damage and bone
marrow changes are the features most closely associated with
subregional cartilage loss. JSW narrowing was demonstrated
to be strongly associated with cartilage loss in weight-bearing
areas. This reflects that JSW change at its narrowest point
may be closely related to cartilage loss in specific subregions.
Lastly, these data also confirm the correlation between carti-
lage volume loss and the severity of symptoms, including
worsening of pain at 24 months.
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